Vyome Holdings (HIND) Amortizatization of Intangibles (2015 - 2019)
Vyome Holdings (HIND) posted quarterly Amortizatization of Intangibles of -$68000.0 for Q3 2019, down 1071.43% year-over-year from $7000.0 in Q3 2018, and down 241.67% quarter-over-quarter from $48000.0 in Q2 2019.
Vyome Holdings (HIND) Amortizatization of Intangibles (2015 - 2019) Analysis & Trends
Vyome Holdings' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at -$68000.0 for Q3 2019.
- In Q3 2019, Amortizatization of Intangibles fell 1071.43% year-over-year to -$68000.0; the TTM figure through Jun 2020 stood at -$68000.0 (down 180.0% YoY), while the FY2019 annual figure was $2000.0, down 94.59% from the prior year.
- Amortizatization of Intangibles for Q3 2019 stood at -$68000.0, down from $48000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $294000.0 in Q4 2015, with the low at -$68000.0 in Q3 2019.
- The 5-year median for Amortizatization of Intangibles is $9000.0 (2016), against an average of $24062.5.
- Peak annual rise in Amortizatization of Intangibles reached 340.0% in 2019, while the deepest fall reached 1071.43% in 2019.
- Vyome Holdings' Amortizatization of Intangibles stood at $294000.0 in 2015, then sank by 96.6% to $10000.0 in 2016, then sank by 40.0% to $6000.0 in 2017, then jumped by 33.33% to $8000.0 in 2018, then sank by 950.0% to -$68000.0 in 2019.
- Business Quant data shows HIND's Amortizatization of Intangibles at -$68000.0 in Q3 2019, $48000.0 in Q2 2019, and $22000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vyome Holdings | 16.07 Mn | 8.18 Mn | 11,658.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -68,000.00 |
| Sep 30, 2019 | -68,000.00 |
| Jun 30, 2019 | 48,000.00 |
| Jun 30, 2019 | 48,000.00 |
| Mar 31, 2019 | 22,000.00 |
| Mar 31, 2019 | 22,000.00 |
| Dec 31, 2018 | 8,000.00 |
| Dec 31, 2018 | 8,000.00 |
| Sep 30, 2018 | 7,000.00 |
| Sep 30, 2018 | 7,000.00 |
| Jun 30, 2018 | 17,000.00 |
| Jun 30, 2018 | 17,000.00 |
| Mar 31, 2018 | 5,000.00 |
| Mar 31, 2018 | 5,000.00 |
| Dec 31, 2017 | 6,000.00 |
| Dec 31, 2017 | 6,000.00 |
| Sep 30, 2017 | -13,000.00 |
| Sep 30, 2017 | -13,000.00 |
| Jun 30, 2017 | -21,000.00 |
| Jun 30, 2017 | -21,000.00 |